Time course response of TLR2−/−EFs and wild-type EFs to APLAs
| Time, h . | TLR2−/−EF . | Wild-type EF . | ||||
|---|---|---|---|---|---|---|
| MCP-1 . | ICAM-1 . | IL-6 . | MCP-1 . | ICAM-1 . | IL-6 . | |
| 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| 4 | 1.46 ± 0.33 | 1.1 ± 0.1 | 1.43 ± 0.6 | 10.07 ± 2.34 | 12.13 ± 5.2 | 37.14 ± 17.1 |
| 8 | 1.46 ± 0.36 | 1.25 ± 0.35 | 1.03 ± 0.12 | 16.74 ± 9.68 | 7.24 ± 2.9 | 44.48 ± 12.2 |
| 12 | 1.33 ± 0.25 | 1.65 ± 0.05 | 1.23 ± 0.26 | 16.26 ± 11.9 | 7.86 ± 0.27 | 62.56 ± 38.34 |
| 16 | 1.1 ± 0.14 | 1.65 ± 0.15 | 1.2 ± 0.21 | 13.34 ± 10.54 | 6.31 ± 2.58 | 38.83 ± 29 |
| 24 | 1.06 ± 0.09 | 1 | 1.16 ± 0.17 | 3.69 ± 0.57 | 2.5 ± 0.35 | 13.11 ± 10.53 |
| Time, h . | TLR2−/−EF . | Wild-type EF . | ||||
|---|---|---|---|---|---|---|
| MCP-1 . | ICAM-1 . | IL-6 . | MCP-1 . | ICAM-1 . | IL-6 . | |
| 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| 4 | 1.46 ± 0.33 | 1.1 ± 0.1 | 1.43 ± 0.6 | 10.07 ± 2.34 | 12.13 ± 5.2 | 37.14 ± 17.1 |
| 8 | 1.46 ± 0.36 | 1.25 ± 0.35 | 1.03 ± 0.12 | 16.74 ± 9.68 | 7.24 ± 2.9 | 44.48 ± 12.2 |
| 12 | 1.33 ± 0.25 | 1.65 ± 0.05 | 1.23 ± 0.26 | 16.26 ± 11.9 | 7.86 ± 0.27 | 62.56 ± 38.34 |
| 16 | 1.1 ± 0.14 | 1.65 ± 0.15 | 1.2 ± 0.21 | 13.34 ± 10.54 | 6.31 ± 2.58 | 38.83 ± 29 |
| 24 | 1.06 ± 0.09 | 1 | 1.16 ± 0.17 | 3.69 ± 0.57 | 2.5 ± 0.35 | 13.11 ± 10.53 |
Results are expressed as fold increase of mRNA from stimulated cells versus unstimulated cells. The results represent the average ± SD for APLAs from 2 different patients and from β2GP1-IgG for TLR2−/−EFs and wild-type EFs. Each APLA was analyzed at least in 2 independent experiments.